GlassScriptPhysician profile
Imran Adam Memon
NPI 1952582157
$3,222.18
in general payments reported to CMS, 2019-2025
27 companies · $620 in 2025
The $620 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $241 · 2021: $339 · 2022: $829 · 2023: $502 · 2024: $481 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.46 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,037.88 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $590.05 | 2020-2023 | Krystexxa |
| Amgen INC. | $485.76 | 2023-2025 | Krystexxa, Tavneos |
| Novo Nordisk INC | $148.45 | 2021-2025 | Ozempic |
| Alexion Pharmaceuticals, INC. | $130.13 | 2022-2025 | Ultomiris |
| Vifor Pharma, INC. | $116.32 | 2020-2024 | Veltassa |
| Takeda Pharmaceuticals U.S.A., INC. | $92.25 | 2022-2025 | Livtencity, Gattex |
| Glaxosmithkline, LLC. | $78.33 | 2021-2023 | Benlysta |
| Calliditas Therapeutics US INC. | $69.17 | 2025 | Tarpeyo |
| Merck Sharp & Dohme LLC | $65.37 | 2025 | Prevymis |
| Mallinckrodt Hospital Products INC. | $49.97 | 2020-2025 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.33 | 2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $34.28 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $25.17 | 2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $24.66 | 2023 | Lupkynis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Travere Therapeutics, INC. | $21.34 | 2023 | |
| Lilly USA, LLC | $20.31 | 2024 | Jardiance |
| Scpharmaceuticals INC. | $19.81 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.62 | 2024 | |
| Daiichi Sankyo INC. | $19.59 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $19.50 | 2021 | |
| Cormedix INC. | $19.28 | 2024 | Defencath |
| Janssen Pharmaceuticals, INC | $18.31 | 2024 | Invega Sustenna |
| Abbott Laboratories | $17.67 | 2022 | |
| Opko Pharmaceuticals, LLC | $14.97 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.